1. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 24(3):421 (2015) PMID 25645727

    Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathwa...
  2. By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.

    Oncotarget 6(4):2315 (2015) PMID 25537513

    Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer thr...
  3. Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.

    The Breast 23(5):690 (2014) PMID 24985755

  4. 2013 San Antonio Breast Cancer Symposium.

    Expert Opinion on Pharmacotherapy 15(8):1191 (2014) PMID 24697336

    The San Antonio Breast Cancer Symposium is considered by researchers and physicians involved in breast cancer management as one of the most important international events on the subject. A dense program of plenary presentations of novel findings, main lectures, poster discussions and displays, i...
  5. Vertebral augmentation with nitinol endoprosthesis: clinical experience in 40 patients with 1-year follow-up.

    CardioVascular and Interventional Radiology 37(1):193 (2014) PMID 23652416

    This study was designed to assess the clinical outcomes of patients treated by vertebral augmentation with nitinol endoprosthesis (VNE) to treat painful vertebral compression fractures. Forty patients with one or more painful osteoporotic VCF, confirmed by MRI and accompanied by back-pain unresp...
  6. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

    The Breast 23(1):44 (2014) PMID 24210572

    Five to 10% of women with newly diagnosed breast cancer have synchronous metastases (de novo stage IV). A further 20% will develop metastases during follow-up (recurring stage IV). We compared the clinical outcomes of women with HER2-positive metastatic breast cancer (MBC) receiving first-line t...
  7. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

    Molecular Oncology 8(1):20 (2014)

    In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2-targeting agents without chemotherapy (CT) in HER2-positive metastatic breast cancer (MBC) patients. The primary tumors of the patients enrolled in this study offered a unique ...
  8. Vertebral augmentation with nitinol endoprosthesis: clinical experience in 40 patients with 1-year follow-up.

    CardioVascular and Interventional Radiology 37(1):193 (2014) PMID 23652416

    This study was designed to assess the clinical outcomes of patients treated by vertebral augmentation with nitinol endoprosthesis (VNE) to treat painful vertebral compression fractures. Forty patients with one or more painful osteoporotic VCF, confirmed by MRI and accompanied by back-pain unresp...
  9. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

    Molecular Oncology 8(1):20 (2014) PMID 24075779

    In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2-targeting agents without chemotherapy (CT) in HER2-positive metastatic breast cancer (MBC) patients. The primary tumors of the patients enrolled in this study offered a unique opportunit...
  10. Biomarkers of drugs targeting HER-family signalling in cancer.

    Journal of Pathology 232(2):219 (2014) PMID 24105684

    The epidermal growth factor receptor family (EGFR/HER) is frequently deregulated in human cancers. Several aberrations at various levels have been successfully exploited as targets for anti-cancer therapies. However, with very few exceptions, drugs targeting HER signalling have shown only modest...
  11. Upfront adjuvant aromatase inhibitors in women with lobular breast cancer.

    European Journal of Cancer 49(15):3376 (2013) PMID 23867125

  12. Upfront adjuvant aromatase inhibitors in women with lobular breast cancer

    European Journal of Cancer 49(15):3376 (2013)

  13. Duration of trastuzumab for HER2-positive breast cancer.

    The Lancet Oncology 14(8):678 (2013) PMID 23764182

  14. Duration of trastuzumab for HER2-positive breast cancer

    The Lancet Oncology 14(8):678 (2013)

  15. Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines.

    Journal of Pathology 229(3):390 (2013) PMID 22806884

    A subgroup of HER2-overexpressing breast tumours co-expresses p95(HER2), a truncated HER2 receptor that retains a functional HER2 kinase domain but lacks the extracellular domain, thus impairing trastuzumab binding. We evaluated p95(HER2) expression in 99 frozen breast carcinoma samples by weste...
  16. Does immediate reconstruction increase postmastectomy surgical site infection?

    Gland surgery 1(3):167 (2012) PMID 25083443 PMCID PMC4115700

  17. Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients.

    Annals of Surgical Oncology 19(12):3755 (2012) PMID 22805871

    This study was designed to evaluate how the omission of axillary dissection would have altered the indication for adjuvant chemotherapy (ACT) in patients with early breast cancer submitted to conservative surgery with one or two positive sentinel lymph nodes (SLNs). We identified 321 women in ou...
  18. Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.

    Expert Opinion on Pharmacotherapy 13(15):2143 (2012) PMID 22984936

    Endocrine therapy is a fundamental component of the therapeutic repertoire for treatment of metastatic, hormone receptor-positive breast cancer. Inevitably, however, tumors develop resistance to these compounds, and overcoming this phenomenon is a key motivator of research in this field. This re...
  19. Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients.

    European Journal of Cancer 48(15):2311 (2012) PMID 22647686

    Nipple-areola sparing mastectomy (NSM) is increasingly used in patients with non-locally advanced breast carcinoma. Literature data on the preoperative assessment of the nipple-areola complex (NAC) are inconsistent. Out of 1359 patients submitted to total mastectomy between 2001 and 2010, we sel...
  20. Clinical and radiological predictors of nipple-areola complex involvement in breast cancer patients

    European Journal of Cancer 48(15):2311 (2012)

    Introduction Nipple-areola sparing mastectomy (NSM) is increasingly used in patients with non-locally advanced breast carcinoma. Literature data on the preoperative assessment of the nipple-areola complex (NAC) are inconsistent.